Barclays maintains Becton Dickinson at Underweight, raises price target to $195 from $165

Barclays kept its Underweight rating on Becton Dickinson but raised its price target to $195 from $165, suggesting a 9.4% downside from the Nov 9 close. Recent analyst price targets for the company range from $200 to $241.

Original reporting
Published Nov 10, 2026, 2:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 2:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Barclays maintains Becton Dickinson at Underweight, raises price target to $195 from $165 — source image
Decision brief

The 30-second read

$BDXNeutralLow
01

Why it matters

The modest target increase may not move the stock significantly, but it signals a slightly more optimistic outlook.

02

Market read

A small analyst upgrade with limited price impact; relevant for short‑term traders monitoring BDX.

03

What to watch

Potential upcoming product launches or contract wins not mentioned could change the outlook.

Relevance 5/10Novelty 4/10Timing: today

Background

Barclays' analyst note updates its valuation for Becton Dickinson, a leading medical device maker.

Company-level read

Ticker impact

$BDXNeutralMedium confidence
Context

Barclays raised its price target on Becton Dickinson to $195 from $165.

Expected impact

likely pressure as the market prices in the lower target

Evidence & confidence

Analyst target increase is modest and still below the stock's recent close, so traders may see limited upside.

Market effects

Minimal impact on the medical devices sector; only reflects one analyst's view.

U.S. market only; no broader regional effect.

Low; the news is specific to BDX and does not affect global markets.

Counterpoint

Some investors may view the target raise as a sign of confidence and could buy on dips.

Key entities

  • Barclays

    Equity research firm providing the price target update.

  • Becton Dickinson

    Medical device manufacturer (ticker BDX).

Related articles

$AAPLMed

New Australian Data Shed Even More Light on Tax Avoidance by Big Tech (and Others), Highlight Need for Better Disclosure in the U.S.

The Australian Taxation Office released country-by-country tax reports, revealing that Apple (25% of profits in Singapore) and Visa (62% of profits in Singapore) booked significant profits in low-tax jurisdictions. Becton Dickinson reported $266.2M pretax income in the Cayman Islands with no local employees. The data highlights discrepancies between U.S. and Australian disclosures, raising concerns about tax transparency.

$BDXMedAI 8/10

Becton, Dickinson and Company Q4 Earnings Call Highlights

Becton, Dickinson (BDX) reported Q4 earnings, with revenue growth in Interventional (7.6%) and BioPharma Systems (7%). The company expects Q1 adjusted EPS of $2.32-$2.37, with full-year margins flat. BDX plans to discuss long-term targets on Dec. 10. Free cash flow rose 42% to $2.9B, with $3.6B returned to shareholders. BDX has a $19B U.S. investment agreement, potentially easing future tariffs.

$BDXHighAI 8/10

Becton Dickinson & Co (BDX) (Q4 2026) Earnings Call Highlights: Strong Q4 Beat, $19

Becton Dickinson (BDX) reported strong Q4 2026 results but issued cautious fiscal 2027 guidance, expecting low single-digit revenue growth due to a 200 basis point Alaris headwind. Adjusted operating margins are expected to remain flat, with inflation and investments offsetting productivity gains. The company's Q1 guidance is conservative, impacted by system cutovers and the Alaris comparison. Tariff relief benefits are not included in the guidance due to uncertainty.